Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal multiple-dose bioavailability trial of chlorphenamine/codeine (CCP 01).

Trial Profile

Pivotal multiple-dose bioavailability trial of chlorphenamine/codeine (CCP 01).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chlorphenamine/codeine (Primary)
  • Indications Common cold; Cough
  • Focus Pharmacokinetics
  • Sponsors Vernalis
  • Most Recent Events

    • 01 May 2015 Vernalis and Tris Pharma received FDA approval of the NDA for Tuzistra XR (chlorpheniramine/codeine), according to a media release; the approval was based on data from this multiple-dose trial and the pivotal single-dose trial.
    • 01 Jul 2014 An NDA was submitted to the US FDA based on results from this trial.
    • 24 Feb 2014 Status changed from not yet recruiting to completed, as reported by a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top